Tadas runs the invaluable Abnormal Returns blog, which provides a daily overview of the best finance and markets writing.
This time of year always seems to be finicky in the markets so it is important to rely on the fundamentals and your thesis.
401 Advisor's Bil DeShurko is a rare breed of manager who values both a bottom-up fundamental and top-down technical approach in his investment model.
Our model has almost 85% of its market value held in 5 holdings: Liberty Interactive, Intuit, Direct TV, Quest Diagnostics, and Starbucks.
Essentially biotech investors assume the role of venture capitalist by funding drug companies with high failure risk.
Is this an opportunity to buy all of those great stocks that “got away from you” in the first quarter run-up, or a portent of nasty things to come?